



CRISPR Therapeutics to Present at Investor Conferences in May

May 12, 2017

BASEL, Switzerland and CAMBRIDGE, Mass., May 12, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics and Samarth Kulkarni, Ph.D., President and Chief Business Officer of CRISPR Therapeutics, will present at two upcoming Investor Conferences in May.

Event: Bank of America Merrill Lynch 2017 Health Care Conference: Gene Therapy and Gene Editing Panel

Date: Wednesday, May 17th

Time: 1:40 PM PDT

Event: UBS Global Healthcare Conference

Date: Tuesday, May 23rd

Time: 1:30 PM EDT

A live webcast of the presentation at the UBS Global Healthcare Conference can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.

MEDIA CONTACTS:

Jennifer Paganelli

WCG on behalf of CRISPR

+1 347-658-8290 jpaganelli@wcgworld.com

INVESTOR CONTACT:

Chris Brinzey

Westwicke Partners for CRISPR

+1 339-970-2843 chris.brinzey@westwicke.com



CRISPR Therapeutics AG